Empirical Finance LLC Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Empirical Finance LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,915 shares of the medical research company’s stock after acquiring an additional 489 shares during the period. Empirical Finance LLC’s holdings in Thermo Fisher Scientific were worth $5,642,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Sierra Legacy Group increased its holdings in shares of Thermo Fisher Scientific by 209.3% in the second quarter. Sierra Legacy Group now owns 1,970 shares of the medical research company’s stock valued at $799,000 after purchasing an additional 1,333 shares during the last quarter. Investidor Profissional Gestao de Recursos Ltda. grew its holdings in Thermo Fisher Scientific by 75.8% in the 2nd quarter. Investidor Profissional Gestao de Recursos Ltda. now owns 25,749 shares of the medical research company’s stock valued at $10,440,000 after buying an additional 11,101 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of Thermo Fisher Scientific by 3.8% in the 2nd quarter. Primecap Management Co. CA now owns 2,406,192 shares of the medical research company’s stock worth $975,615,000 after acquiring an additional 88,890 shares during the last quarter. America First Investment Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $22,666,000. Finally, Traub Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $107,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.6%

NYSE:TMO opened at $576.01 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock’s fifty day moving average is $531.35 and its two-hundred day moving average is $470.43. The stock has a market capitalization of $216.41 billion, a price-to-earnings ratio of 33.28, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the business earned $5.28 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michel Lagarde sold 4,638 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total value of $2,756,919.96. Following the transaction, the chief operating officer directly owned 23,480 shares of the company’s stock, valued at $13,956,981.60. The trade was a 16.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 51,845 shares of company stock worth $28,956,952 over the last 90 days. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Barclays raised their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Leerink Partners increased their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.